| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.22 | 3e-09 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.29 | 2e-08 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.22 | 5e-07 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.32 | 6e-07 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.19 | 8e-07 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.2 | 1e-06 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.28 | 4e-06 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.14 | 1e-05 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-05 |